Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.50
NYSE:ABT's Cash to Debt is ranked lower than
74% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. NYSE:ABT: 0.50 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:ABT' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: 0.3 Max: 1.28
Current: 0.5
0.05
1.28
Equity to Asset 0.52
NYSE:ABT's Equity to Asset is ranked lower than
67% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NYSE:ABT: 0.52 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:ABT' s Equity to Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.44 Max: 0.59
Current: 0.52
0.37
0.59
Interest Coverage 11.80
NYSE:ABT's Interest Coverage is ranked lower than
72% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: 69.16 vs. NYSE:ABT: 11.80 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:ABT' s Interest Coverage Range Over the Past 10 Years
Min: 4.91  Med: 11.51 Max: 18.07
Current: 11.8
4.91
18.07
F-Score: 5
Z-Score: 3.68
M-Score: -2.37
WACC vs ROIC
11.97%
69.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 13.95
NYSE:ABT's Operating margin (%) is ranked higher than
80% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. NYSE:ABT: 13.95 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:ABT' s Operating margin (%) Range Over the Past 10 Years
Min: 9.09  Med: 17.49 Max: 20.28
Current: 13.95
9.09
20.28
Net-margin (%) 11.08
NYSE:ABT's Net-margin (%) is ranked higher than
78% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 1.24 vs. NYSE:ABT: 11.08 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:ABT' s Net-margin (%) Range Over the Past 10 Years
Min: 7.64  Med: 13.54 Max: 18.68
Current: 11.08
7.64
18.68
ROE (%) 10.67
NYSE:ABT's ROE (%) is ranked higher than
72% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. NYSE:ABT: 10.67 )
Ranked among companies with meaningful ROE (%) only.
NYSE:ABT' s ROE (%) Range Over the Past 10 Years
Min: 9.78  Med: 21.56 Max: 28.49
Current: 10.67
9.78
28.49
ROA (%) 5.51
NYSE:ABT's ROA (%) is ranked higher than
69% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 0.05 vs. NYSE:ABT: 5.51 )
Ranked among companies with meaningful ROA (%) only.
NYSE:ABT' s ROA (%) Range Over the Past 10 Years
Min: 4.68  Med: 8.81 Max: 12.12
Current: 5.51
4.68
12.12
ROC (Joel Greenblatt) (%) 28.84
NYSE:ABT's ROC (Joel Greenblatt) (%) is ranked higher than
76% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 4.17 vs. NYSE:ABT: 28.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:ABT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 22.28  Med: 45.66 Max: 65.75
Current: 28.84
22.28
65.75
Revenue Growth (3Y)(%) -18.80
NYSE:ABT's Revenue Growth (3Y)(%) is ranked lower than
81% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. NYSE:ABT: -18.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:ABT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.8  Med: 8.65 Max: 13.7
Current: -18.8
-18.8
13.7
EBITDA Growth (3Y)(%) -21.00
NYSE:ABT's EBITDA Growth (3Y)(%) is ranked lower than
84% of the 192 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. NYSE:ABT: -21.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:ABT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -21.2  Med: 4.55 Max: 31.6
Current: -21
-21.2
31.6
EPS Growth (3Y)(%) 15.90
NYSE:ABT's EPS Growth (3Y)(%) is ranked higher than
70% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. NYSE:ABT: 15.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:ABT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -65.6  Med: 6.6 Max: 48.8
Current: 15.9
-65.6
48.8
» NYSE:ABT's 10-Y Financials

Financials (Next Earnings Date: 2016-10-19)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ABT Guru Trades in Q3 2015

John Hussman 3,000 sh (New)
Jim Simons 1,348,400 sh (New)
Paul Tudor Jones 59,714 sh (+335.87%)
Ray Dalio 82,457 sh (+189.76%)
Joel Greenblatt 1,455,289 sh (+39.49%)
George Soros 731,481 sh (+21.47%)
Murray Stahl 21,503 sh (+15.59%)
First Eagle Investment 6,825,289 sh (+15.36%)
Robert Olstein 176,000 sh (+10.69%)
Diamond Hill Capital 8,385,413 sh (+4.00%)
Ken Fisher 15,254 sh (+1.73%)
Jeff Auxier 78,922 sh (+1.41%)
John Buckingham 91,905 sh (+0.38%)
Robert Bruce 230,915 sh (unchged)
Tom Russo 85,400 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
David Carlson 600,000 sh (unchged)
Dodge & Cox 30,268 sh (-3.20%)
PRIMECAP Management 16,677,764 sh (-5.97%)
Mairs and Power 319,343 sh (-6.58%)
Vanguard Health Care Fund 6,938,700 sh (-8.60%)
Richard Pzena 5,188,346 sh (-18.17%)
Jeremy Grantham 6,469,218 sh (-31.90%)
Pioneer Investments 1,213,173 sh (-34.84%)
Mario Gabelli 17,625 sh (-71.12%)
» More
Q4 2015

ABT Guru Trades in Q4 2015

Robert Olstein 201,000 sh (+14.20%)
Ken Fisher 17,286 sh (+13.32%)
Murray Stahl 22,503 sh (+4.65%)
Diamond Hill Capital 8,621,765 sh (+2.82%)
Westport Asset Management 200,000 sh (unchged)
Jeff Auxier 78,922 sh (unchged)
Tom Russo 85,400 sh (unchged)
Mario Gabelli 17,625 sh (unchged)
Dodge & Cox 30,268 sh (unchged)
Robert Bruce 230,915 sh (unchged)
David Carlson 600,000 sh (unchged)
Spiros Segalas 9,871,440 sh (unchged)
Jim Simons Sold Out
John Hussman Sold Out
Pioneer Investments 1,212,972 sh (-0.02%)
Mairs and Power 318,918 sh (-0.13%)
PRIMECAP Management 16,643,039 sh (-0.21%)
John Buckingham 91,506 sh (-0.43%)
First Eagle Investment 6,671,344 sh (-2.26%)
Richard Pzena 4,861,129 sh (-6.31%)
George Soros 664,181 sh (-9.20%)
Jeremy Grantham 5,653,313 sh (-12.61%)
Vanguard Health Care Fund 6,027,260 sh (-13.14%)
Ray Dalio 38,857 sh (-52.88%)
Paul Tudor Jones 13,100 sh (-78.06%)
Joel Greenblatt 98,838 sh (-93.21%)
» More
Q1 2016

ABT Guru Trades in Q1 2016

Joel Greenblatt 861,862 sh (+771.99%)
Diamond Hill Capital 10,198,087 sh (+18.28%)
First Eagle Investment 7,507,515 sh (+12.53%)
Robert Olstein 220,000 sh (+9.45%)
Murray Stahl 22,778 sh (+1.22%)
PRIMECAP Management 16,812,839 sh (+1.02%)
Mairs and Power 319,391 sh (+0.15%)
Robert Bruce 230,915 sh (unchged)
Vanguard Health Care Fund 6,027,260 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
David Carlson 600,000 sh (unchged)
Paul Tudor Jones Sold Out
Jeff Auxier 78,672 sh (-0.32%)
Pioneer Investments 1,201,725 sh (-0.93%)
Dodge & Cox 29,268 sh (-3.30%)
Richard Pzena 4,642,170 sh (-4.50%)
John Buckingham 87,087 sh (-4.83%)
Ken Fisher 15,413 sh (-10.84%)
Mario Gabelli 13,695 sh (-22.30%)
Jeremy Grantham 3,713,180 sh (-34.32%)
George Soros 419,181 sh (-36.89%)
Ray Dalio 11,400 sh (-70.66%)
Tom Russo 20,400 sh (-76.11%)
Spiros Segalas 9,668,976 sh (-2.05%)
» More
Q2 2016

ABT Guru Trades in Q2 2016

Manning & Napier Advisors, Inc 152,221 sh (New)
Paul Tudor Jones 26,300 sh (New)
Stanley Druckenmiller 385,400 sh (New)
Ray Dalio 104,100 sh (+813.16%)
Vanguard Health Care Fund 10,508,900 sh (+74.36%)
John Buckingham 133,574 sh (+53.38%)
Mairs and Power 406,484 sh (+27.27%)
Diamond Hill Capital 11,968,670 sh (+17.36%)
Jeremy Grantham 4,345,234 sh (+17.02%)
Richard Pzena 5,327,448 sh (+14.76%)
Murray Stahl 22,978 sh (+0.88%)
Jeff Auxier 78,672 sh (unchged)
Jeremy Grantham 173,800 sh (unchged)
Dodge & Cox 29,268 sh (unchged)
Robert Bruce 230,915 sh (unchged)
Robert Olstein Sold Out
Mario Gabelli 13,685 sh (-0.07%)
PRIMECAP Management 16,478,409 sh (-1.99%)
Pioneer Investments 978,987 sh (-18.53%)
Tom Russo 16,400 sh (-19.61%)
Ken Fisher 12,387 sh (-19.63%)
George Soros 329,181 sh (-21.47%)
Westport Asset Management 145,000 sh (-27.50%)
David Carlson 420,000 sh (-30.00%)
First Eagle Investment 2,974,455 sh (-60.38%)
Joel Greenblatt 130,054 sh (-84.91%)
Spiros Segalas 7,490,086 sh (-22.53%)
» More
» Details

Insider Trades

Latest Guru Trades with ABT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NYSE:SYK, NYSE:BSX, NAS:ISRG, NYSE:ZBH, NYSE:EW, NYSE:STJ, OTCPK:SNNUF, OTCPK:SONVY, NYSE:VAR, NYSE:TFX, NAS:ALGN, OTCPK:SDMHF, OTCPK:CHEOY, OTCPK:WILLF, NAS:ABMD, OTCPK:FSPKF, OTCPK:EKTAF, NAS:NUVA, OTCPK:GGNDF, NAS:IART » details
Traded in other countries:ABT.Argentina, ABTT34.Brazil, ABT.Chile, ABL.Germany, ABT.Mexico, ABT.Switzerland, ABT.UK,
Abbott Laboratories discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the United States.

Abbott Laboratories is an Illinois corporation, incorporated in 1900. The Company discovers, develops, manufactures and sells health care products. Its services are sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians' offices and government agencies internationally. Its segments are Established Pharmaceutical Products, Nutritional Products, Diagnostic Products and Vascular Product. The Established Pharmaceutical Products is engaged in the International sales of various branded generic pharmaceutical products. Nutritional Products sells broad line of adult and pediatric nutritional products internationally. Diagnostic Products sells diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. This segment also includes Core Laboratories Diagnostics, Molecular Diagnostics, Point of Care and Ibis diagnostic divisions. Vascular Products sells coronary, endovascular, structural heart, vessel closure and other medical device products.

Ratios

vs
industry
vs
history
P/E(ttm) 27.60
ABT's P/E(ttm) is ranked lower than
53% of the 167 Companies
in the Global Medical Devices industry.

( Industry Median: 27.08 vs. ABT: 27.60 )
Ranked among companies with meaningful P/E(ttm) only.
ABT' s P/E(ttm) Range Over the Past 10 Years
Min: 5.78  Med: 10.33 Max: 35.05
Current: 27.6
5.78
35.05
Forward P/E 16.95
ABT's Forward P/E is ranked higher than
86% of the 56 Companies
in the Global Medical Devices industry.

( Industry Median: 23.87 vs. ABT: 16.95 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 32.31
ABT's PE(NRI) is ranked lower than
57% of the 167 Companies
in the Global Medical Devices industry.

( Industry Median: 27.22 vs. ABT: 32.31 )
Ranked among companies with meaningful PE(NRI) only.
ABT' s PE(NRI) Range Over the Past 10 Years
Min: 5.93  Med: 20.51 Max: 250.57
Current: 32.31
5.93
250.57
Price/Owner Earnings (ttm) 59.89
ABT's Price/Owner Earnings (ttm) is ranked lower than
75% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 31.34 vs. ABT: 59.89 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ABT' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 4.46  Med: 9.32 Max: 523.97
Current: 59.89
4.46
523.97
P/B 2.96
ABT's P/B is ranked higher than
51% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. ABT: 2.96 )
Ranked among companies with meaningful P/B only.
ABT' s P/B Range Over the Past 10 Years
Min: 1.39  Med: 2.24 Max: 3.34
Current: 2.96
1.39
3.34
P/S 3.03
ABT's P/S is ranked higher than
52% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 3.23 vs. ABT: 3.03 )
Ranked among companies with meaningful P/S only.
ABT' s P/S Range Over the Past 10 Years
Min: 0.96  Med: 1.53 Max: 3.78
Current: 3.03
0.96
3.78
PFCF 36.98
ABT's PFCF is ranked lower than
66% of the 100 Companies
in the Global Medical Devices industry.

( Industry Median: 30.18 vs. ABT: 36.98 )
Ranked among companies with meaningful PFCF only.
ABT' s PFCF Range Over the Past 10 Years
Min: 4.38  Med: 8.8 Max: 40.16
Current: 36.98
4.38
40.16
POCF 21.99
ABT's POCF is ranked lower than
52% of the 132 Companies
in the Global Medical Devices industry.

( Industry Median: 21.53 vs. ABT: 21.99 )
Ranked among companies with meaningful POCF only.
ABT' s POCF Range Over the Past 10 Years
Min: 3.82  Med: 6.61 Max: 23.88
Current: 21.99
3.82
23.88
EV-to-EBIT 26.30
ABT's EV-to-EBIT is ranked lower than
59% of the 164 Companies
in the Global Medical Devices industry.

( Industry Median: 22.51 vs. ABT: 26.30 )
Ranked among companies with meaningful EV-to-EBIT only.
ABT' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.4  Med: 9.2 Max: 28.6
Current: 26.3
5.4
28.6
EV-to-EBITDA 16.69
ABT's EV-to-EBITDA is ranked higher than
50% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 16.88 vs. ABT: 16.69 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 6.8 Max: 18.1
Current: 16.69
4.3
18.1
Shiller P/E 15.12
ABT's Shiller P/E is ranked higher than
91% of the 47 Companies
in the Global Medical Devices industry.

( Industry Median: 42.11 vs. ABT: 15.12 )
Ranked among companies with meaningful Shiller P/E only.
ABT' s Shiller P/E Range Over the Past 10 Years
Min: 9  Med: 12.65 Max: 18.1
Current: 15.12
9
18.1
Current Ratio 1.50
ABT's Current Ratio is ranked lower than
79% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.56 vs. ABT: 1.50 )
Ranked among companies with meaningful Current Ratio only.
ABT' s Current Ratio Range Over the Past 10 Years
Min: 0.75  Med: 1.4 Max: 2.36
Current: 1.5
0.75
2.36
Quick Ratio 1.17
ABT's Quick Ratio is ranked lower than
74% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 1.94 vs. ABT: 1.17 )
Ranked among companies with meaningful Quick Ratio only.
ABT' s Quick Ratio Range Over the Past 10 Years
Min: 0.55  Med: 1.13 Max: 2.07
Current: 1.17
0.55
2.07
Days Inventory 111.59
ABT's Days Inventory is ranked higher than
60% of the 280 Companies
in the Global Medical Devices industry.

( Industry Median: 132.35 vs. ABT: 111.59 )
Ranked among companies with meaningful Days Inventory only.
ABT' s Days Inventory Range Over the Past 10 Years
Min: 76.02  Med: 86.98 Max: 117.89
Current: 111.59
76.02
117.89
Days Sales Outstanding 63.34
ABT's Days Sales Outstanding is ranked higher than
57% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 68.07 vs. ABT: 63.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.44  Med: 69.2 Max: 77.62
Current: 63.34
58.44
77.62
Days Payable 47.42
ABT's Days Payable is ranked lower than
59% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 57.81 vs. ABT: 47.42 )
Ranked among companies with meaningful Days Payable only.
ABT' s Days Payable Range Over the Past 10 Years
Min: 35.38  Med: 39.04 Max: 47.42
Current: 47.42
35.38
47.42

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.45
ABT's Dividend Yield is ranked higher than
80% of the 163 Companies
in the Global Medical Devices industry.

( Industry Median: 1.68 vs. ABT: 2.45 )
Ranked among companies with meaningful Dividend Yield only.
ABT' s Dividend Yield Range Over the Past 10 Years
Min: 1.41  Med: 5.05 Max: 7.9
Current: 2.45
1.41
7.9
Dividend Payout 0.78
ABT's Dividend Payout is ranked lower than
83% of the 114 Companies
in the Global Medical Devices industry.

( Industry Median: 0.39 vs. ABT: 0.78 )
Ranked among companies with meaningful Dividend Payout only.
ABT' s Dividend Payout Range Over the Past 10 Years
Min: 0.34  Med: 0.5 Max: 6.5
Current: 0.78
0.34
6.5
Dividend Growth (3y) -22.40
ABT's Dividend Growth (3y) is ranked lower than
88% of the 76 Companies
in the Global Medical Devices industry.

( Industry Median: 9.10 vs. ABT: -22.40 )
Ranked among companies with meaningful Dividend Growth (3y) only.
ABT' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -31.2  Med: 9.2 Max: 12.4
Current: -22.4
-31.2
12.4
Forward Dividend Yield 2.50
ABT's Forward Dividend Yield is ranked higher than
80% of the 154 Companies
in the Global Medical Devices industry.

( Industry Median: 1.76 vs. ABT: 2.50 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.02
ABT's Yield on cost (5-Year) is ranked lower than
67% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. ABT: 1.02 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ABT' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.59  Med: 2.12 Max: 3.28
Current: 1.02
0.59
3.28
3-Year Average Share Buyback Ratio 1.30
ABT's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 211 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. ABT: 1.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.8  Med: -0.2 Max: 1.3
Current: 1.3
-0.8
1.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 10.92
ABT's Price/Tangible Book is ranked lower than
80% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 4.42 vs. ABT: 10.92 )
Ranked among companies with meaningful Price/Tangible Book only.
ABT' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.1  Med: 9.34 Max: 466.55
Current: 10.92
3.1
466.55
Price/Projected FCF 1.06
ABT's Price/Projected FCF is ranked higher than
82% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. ABT: 1.06 )
Ranked among companies with meaningful Price/Projected FCF only.
ABT' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.36  Med: 0.83 Max: 1.93
Current: 1.06
0.36
1.93
Price/Median PS Value 1.99
ABT's Price/Median PS Value is ranked lower than
86% of the 253 Companies
in the Global Medical Devices industry.

( Industry Median: 1.06 vs. ABT: 1.99 )
Ranked among companies with meaningful Price/Median PS Value only.
ABT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.65  Med: 1.14 Max: 2.39
Current: 1.99
0.65
2.39
Price/Graham Number 3.95
ABT's Price/Graham Number is ranked lower than
71% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. ABT: 3.95 )
Ranked among companies with meaningful Price/Graham Number only.
ABT' s Price/Graham Number Range Over the Past 10 Years
Min: 1.17  Med: 2.38 Max: 20.86
Current: 3.95
1.17
20.86
Earnings Yield (Greenblatt) (%) 3.80
ABT's Earnings Yield (Greenblatt) (%) is ranked higher than
70% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. ABT: 3.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ABT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.5  Med: 10.9 Max: 18.5
Current: 3.8
3.5
18.5
Forward Rate of Return (Yacktman) (%) -11.33
ABT's Forward Rate of Return (Yacktman) (%) is ranked lower than
88% of the 118 Companies
in the Global Medical Devices industry.

( Industry Median: 7.67 vs. ABT: -11.33 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ABT' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -11.8  Med: 16.35 Max: 31.9
Current: -11.33
-11.8
31.9

More Statistics

Revenue (TTM) (Mil) $20,556
EPS (TTM) $ 1.51
Beta1.54
Short Percentage of Float4.72%
52-Week Range $36.00 - 46.38
Shares Outstanding (Mil)1,470.00

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 20,950 23,547 23,350 24,643
EPS ($) 2.19 2.43 2.69 2.90
EPS w/o NRI ($) 2.19 2.43 2.69 2.90
EPS Growth Rate
(3Y to 5Y Estimate)
8.22%
Dividends Per Share ($) 1.02 1.10 1.22
» More Articles for NYSE:ABT

Headlines

Articles On GuruFocus.com
J&J Finally Returning to Its Roots in Diversity? Sep 26 2016 
AbbVie Joins BioArctic in Fight Against Parkinson’s Disease Sep 20 2016 
Abbott Method for Assessing Red Blood Cells Receives Patent Sep 19 2016 
Medical Companies Offer Good Value Opportunities Sep 16 2016 
John Rogers Comments on Abbott Laboratories Aug 18 2016 
John Rogers' Ariel Focus Fund 2nd Quarter Commentary Aug 18 2016 
KEELEY Mid Cap Dividend Value Fund 2nd Quarter Commentary Aug 04 2016 
Weekly CEO Buys: Abbott Laboratories, GE, OPKO Health Jul 31 2016 
Becton Dickinson: 19% EPS Growth With Good Dividends Jun 26 2016 
Opinions Differ on Abbott Deal to Acquire St. Jude's Medical Jun 18 2016 

More From Other Websites
J&J Finally Returning to Its Roots in Diversity? Sep 26 2016
AbbVie (ABBV) HCV Combination Drug Positive in Phase IIIb Sep 26 2016
The Rationale behind Johnson & Johnson’s Acquisition of Abbott Medical Optics Sep 23 2016
Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO Sep 23 2016
Disease-related malnutrition costs U.S. $15.5 bln annually - study Sep 21 2016
Malnutrition Adds $15.5 Billion Annually to Direct U.S. Medical Costs Sep 21 2016
The Zacks Analyst Blog Highlights: Abbott Labs, Comcast, Goldman Sachs, Microsoft and Philip Morris Sep 21 2016
Abbott Hosts Conference Call for Third-Quarter Earnings Sep 21 2016
Top Research Reports for Goldman Sachs, Comcast & Abbott Labs Sep 20 2016
[$$] Abbott's Deal With JNJ Is Good Strategy Sep 20 2016
Fueling Performance with Fat: EAS® Launches First Ketogenic Meal Replacement For Athletes Sep 20 2016
Abbott Laboratories -- Moody's expectations for Abbott's ratings unchanged following news of medical... Sep 19 2016
Abbott Method for Assessing Red Blood Cells Receives Patent Sep 19 2016
Abbott's Eye Deal Isn't About Alere Sep 19 2016
Credit Suisse Can Clearly See Why Johnson & Johnson Acquired Abbott's Optics Division Sep 19 2016
Blog Coverage Johnson and Johnson Acquires Abbott Laboratories Optic Unit Sep 19 2016
J&J (JNJ) to Buy Abbott's Vision Care Unit for $4.3 Billion Sep 19 2016
Tesla, TerraForm, and Johnson & Johnson Among the Biggest Weekend Newsmakers Sep 18 2016
AP Top Extended Financial Headlines at 11:47 a.m. EDT Sep 17 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)